View Financial HealthPrime Medicine 配当と自社株買い配当金 基準チェック /06Prime Medicine配当金を支払った記録がありません。主要情報n/a配当利回り-21.0%バイバック利回り総株主利回り-21.0%将来の配当利回り0%配当成長n/a次回配当支払日n/a配当落ち日n/a一株当たり配当金n/a配当性向n/a最近の配当と自社株買いの更新更新なしすべての更新を表示Recent updatesお知らせ • Jun 22Prime Medicine Receives U.S. Fda Regenerative Medicine Advanced Therapy Designation for Pm359 for the Treatment of Chronic Granulomatous DiseasePrime Medicine, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to PM359, an investigational autologous Prime Edited hematopoietic stem cell therapy for the treatment of p47phox-deficient chronic granulomatous disease (CGD). RMAT designation was granted based on Phase 1/2 clinical data, including data previously published in The New England Journal of Medicine, and will provide the benefits of intensive FDA guidance and expedited review through the program’s development. The combination of RMAT, Fast Track, Orphan Drug, and Rare Pediatric Disease Designations underscores the seriousness of CGD and the need for transformative therapies that deliver durable benefit, while positioning us to engage with the FDA on the most efficient path to a Biologics License Application. RMAT designation was established under the 21st Century Cures Act to expedite the development and review of regenerative medicine therapies intended to treat serious or life-threatening diseases when preliminary clinical evidence indicates the therapy has the potential to address unmet medical need. RMAT designation provides all the benefits of Fast Track and Breakthrough Therapy Designations, including intensive FDA interaction, discussions on surrogate or intermediate endpoints that may support accelerated approval, and eligibility for rolling and priority review of a future Biologics License Application. The initial clinical trial results were reported in the December 2025 publication in The New England Journal of Medicine. The data demonstrate that a single dose of PM359 drove rapid engraftment and a durable, clinically meaningful restoration of immune cell function in both treated patients, with neutrophil activity well above the level associated with clinical benefit and a safety profile consistent with busulfan-based conditioning alone. The findings support the potential of PM359 to deliver a one-time, disease-modifying treatment for patients with p47phox-deficient CGD. PM359 is an investigational autologous hematopoietic stem cell therapy designed to correct the delGT mutation in NCF1, the most prevalent disease-causing mutation in p47phox-deficient CGD. PM359 is being evaluated in an ongoing Phase 1/2, multinational, first-in-human trial. In addition to RMAT designation, PM359 has received Fast Track, Orphan Drug, and Rare Pediatric Disease Designations from the FDA. Chronic granulomatous disease (CGD) is a rare inherited hematologic disorder characterized by susceptibility to severe, difficult-to-treat infections and inflammatory and autoimmune complications. CGD is caused by mutations in any one of the subunits comprising the NADPH oxidase complex, which is required for phagocytic cells, in particular neutrophils, to destroy many invasive microorganisms. CGD causative mutations are estimated to occur in between one in 100,000 and one in 200,000 births in the United States, with the p47phox form accounting for approximately 25% of cases. Current standard of care relies on lifelong antimicrobial prophylaxis and, in select cases, allogeneic hematopoietic stem cell transplantation, which carries significant morbidity and is not accessible to all patients. There are no approved gene editing therapies for CGD.お知らせ • Jun 19Prime Medicine, Inc. Receives New Zealand Clearance For Clinical Trial Application For PM577a In H1069Q-Mutated Wilson DiseasePrime Medicine, Inc. announced that the New Zealand Medicines and Medical Devices Safety Authority (Medsafe) has cleared the Company’s Clinical Trial Application (CTA) for PM577a, an investigational Prime Editor for Wilson Disease (WD). The clearance represents the first clinical authorization for an in vivo Prime Editing therapy from Prime Medicine and enables the initiation of the Company’s global Phase 1/2 study. The Phase 1/2 clinical trial is an open-label, global, first-in-human study designed to evaluate the safety, tolerability, biological activity, and efficacy of ascending doses of PM577a in adults and adolescents with WD. The study will initially enroll adults who are clinically stable on standard-of-care therapy. Biological activity and efficacy assessments may include copper efflux by 64Cu PET, serum ceruloplasmin, non-ceruloplasmin bound copper, 24-hour urinary copper excretion, and hepatic copper by biopsy. PM577 is a family of LNP-formulated Prime Editing products designed to correct pathogenic ATP7B mutations in hepatocytes via a single intravenous infusion. Prime Medicine’s initial candidate, PM577a, targets the ATP7B H1069Q allele, which accounts for approximately 30–50% of WD-associated variants in the United States and Europe. The Company intends to develop additional products to address the majority of pathogenic variants on a global basis. Currently, a follow-on candidate is in pre-clinical development targeting R778L, the most common mutant allele in East Asian populations.分析記事 • Jun 18Is Prime Medicine (NASDAQ:PRME) In A Good Position To Invest In Growth?Just because a business does not make any money, does not mean that the stock will go down. For example, although...Seeking Alpha • Jun 13Prime Medicine's Prime Editing Is Worth The RiskSummary Prime Medicine's PM359 data gives the stock some early human validation for its main value driver: Prime Editing. PM359 was essentially their most advanced application of Prime Editing, even though CGD is a relatively niche market because it's a rare disease. Management decided to deprioritize PM359, and instead, it’s now focused on applying Prime Editing towards larger TAMs like Wilson Disease and AATD. PRME will probably have a lot of interest if they look for new R&D partnerships, which could also help them with financing if they materialize. So, even though I reckon there’s still some dilution and clinical trial risks, PRME’s potentially revolutionary gene editing platform makes it a viable speculative 'Buy.' Read the full article on Seeking Alphaお知らせ • Apr 25Prime Medicine, Inc., Annual General Meeting, Jun 05, 2026Prime Medicine, Inc., Annual General Meeting, Jun 05, 2026.お知らせ • Apr 16Prime Medicine, Inc. Appoints Svetlana Makhni as Chief Financial OfficerPrime Medicine, Inc. announced the appointment of Svetlana Makhni as Chief Financial Officer (CFO). Ms. Makhni will oversee Prime Medicine’s financial operations and strategy, including investor relations, financial planning and analysis, and corporate development. Ms. Makhni brings over 20 years of experience across multiple biotechnology and healthcare CFO and investment banking roles. Prior to joining Prime Medicine, she served as CFO of Marengo Therapeutics, a clinical-stage immuno-oncology company, where she led all aspects of the finance organization, including business development, investor relations and corporate development. In this role, Ms. Makhni played a key role in the execution of multiple high-value strategic partnerships, including transactions with Ipsen and Gilead Sciences. Previously, Ms. Makhni served as CFO of Escient Pharmaceuticals and CFO and Head of Operations at Bierman ABA. Earlier in her career, Ms. Makhni spent over a decade in investment banking and financial services at BMO Capital Markets, Goldman Sachs, Westbrook Partners and The Blackstone Group, advising public and private companies on equity and debt financings, mergers and acquisitions, and other strategic transactions. Ms. Makhni holds an M.B.A. from Harvard Business School and a B.S. from the Wharton School of the University of Pennsylvania.お知らせ • Nov 07Prime Medicine, Inc. has filed a Follow-on Equity Offering in the amount of $200 million.Prime Medicine, Inc. has filed a Follow-on Equity Offering in the amount of $200 million. Security Name: Common Stock Security Type: Common Stock Transaction Features: At the Market Offeringお知らせ • Nov 04Prime Medicine, Inc. Appoints Matthew Hawryluk as Chief Business OfficerPrime Medicine, Inc. announced the appointment of Matthew Hawryluk, Ph.D., M.B.A. as Chief Business Officer (CBO). Dr. Hawryluk will lead Primes corporate and business development initiatives, corporate strategy, and alliance management functions, advancing the companys efforts to expand the reach of Prime Editing through strategic partnerships and collaborations. Dr. Hawryluk joins Prime Medicine with nearly two decades of leadership experience spanning business development, strategy, and corporate operations in the biotechnology industry. Most recently, he served as Chief Business Officer at AIRNA Corporation, where he led corporate and business development, finance, and investor relations, and played a key role in securing an oversubscribed $155 million Series B financing. Dr. Hawryluk served for nearly a decade as Executive Vice President and Chief Business Officer at Gritstone bio, Inc., guiding its growth from early stage to a public company and spearheading its expansion into infectious diseases. He led transactions totaling more than $2.5 billion in potential value, including landmark collaborations with Gilead Sciences, bluebird bio, and multiple government and nonprofit organizations such as BARDA, CEPI, NIAID, and the Bill &Melinda Gates Foundation. Earlier in his career, Dr. Hawryluk held senior roles at Foundation Medicine, where he was instrumental in forging the companys transformative strategic partnership and majority acquisition by Roche/Genentech. His experience also includes business development roles at Thermo Fisher Scientific and work in venture capital and translational science. Dr. Hawryluk holds a Ph.D. in Cell Biology and Protein Biochemistry from the University of Pittsburgh School of Medicine, an M.B.A. from the Carnegie Mellon University Tepper School of Business, and a B.S. in Biochemistry from the University of Notre Dame. Dr. Hawryluk serves on the Boards of Directors of Predictive Oncology Inc. and OuroTech, Inc. (Pear Bio).お知らせ • Aug 01Prime Medicine, Inc. has completed a Follow-on Equity Offering in the amount of $125.4 million.Prime Medicine, Inc. has completed a Follow-on Equity Offering in the amount of $125.4 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 38,000,000 Price\Range: $3.3 Discount Per Security: $0.198お知らせ • Jul 31Prime Medicine, Inc. has filed a Follow-on Equity Offering.Prime Medicine, Inc. has filed a Follow-on Equity Offering. Security Name: Common Stock Security Type: Common Stockお知らせ • Jun 30+ 4 more updatesPrime Medicine, Inc.(NasdaqGM:PRME) dropped from Russell 3000E Growth IndexPrime Medicine, Inc.(NasdaqGM:PRME) dropped from Russell 3000E Growth Indexお知らせ • May 21Prime Medicine, Inc. Announces Breakthrough Clinical Data Showing Rapid Restoration of DHR Positivity After Single Infusion of PM359Prime Medicine, Inc. announced positive initial data from the first patient dosed in its ongoing Phase 1/2 clinical study of PM359 in Chronic Granulomatous Disease (CGD). Preliminary results from the first patient demonstrated that PM359 was well-tolerated, showed rapid engraftment and restored NADPH oxidase activity to well above the threshold for clinical benefit, as measured by the dihydrorhodamine (DHR) assay. Going forward, Prime Medicine will focus its resources on advancing its in vivo liver franchise, where the Company is advancing programs to cure two of the largest genetic liver diseases, Wilson's Disease and Alpha-1 Antitrypsin Deficiency (AATD). Prime Medicine will also continue its in vivo Cystic Fibrosis program with support from the Cystic Fibrosis Foundation, and its efforts to develop Prime Edited CAR-T products for hematology, immunology and oncology in partnership with Bristol Myers Squibb. In addition, Prime Medicine will continue to pursue additional business development opportunities to accelerate innovation, ensure the broadest application of Prime Editing, and further bolster its financial resources. PM359 comprisesautologous hematopoietic stem cells (HSCs) modified ex vivo using Prime Editors that have been designed to correct a high percentage of cells containing the disease-causing mutation. PM359 has received rare pediatric drug designation and orphan drug designation from the U.S. Food and Drug Administration. Chronic Granulomatous disease (CGD) is a rare inherited hematologic disorder characterized by susceptibility to severe, difficult-to-treat infections, and inflammatory/autoimmune complications.お知らせ • May 20+ 3 more updatesPrime Medicine, Inc. Provides Pipeline Prioritization UpdatePrime Medicine, Inc. announced a strategic restructuring, including the deprioritization of its Chronic Granulomatous Disease (CGD) programs. Prime Medicine is currently advancing in vivo programs to cure two of the largest genetic liver diseases, Wilson’s Disease and Alpha-1 Antitrypsin Deficiency (AATD), with initial clinical data from both programs expected in 2027. Prime Medicine will also continue its in vivo Cystic Fibrosis program with support from the Cystic Fibrosis Foundation, and its efforts to develop Prime Edited CAR-T products for hematology, immunology and oncology in partnership with Bristol Myers Squibb. In addition, Prime Medicine will continue to pursue additional business development opportunities to accelerate innovation, ensure the broadest application of Prime Editing, and further bolster its financial resources. Prime Medicine will focus its internal efforts on the development of in vivo programs for the treatment of Wilson’s Disease and AATD, two of the largest genetic liver diseases. Prime Medicine expects to file an investigational new drug (IND) and/or clinical trial application (CTA) for its Wilson’s Disease program in the first half of 2026 and for its AATD program in mid-2026; initial clinical data from both programs are expected in 2027. Wilson’s Disease: Wilson’s Disease is a rare and severe disorder caused by excess copper accumulation in the liver and brain that can lead to liver failure and neurocognitive decline and can be fatal without a liver transplant. There are currently no approved disease-modifying therapies for Wilson’s Disease, which affects more than 20,000 people in the United States and European Union. AATD: AATD is a progressive, genetic disorder caused by mutations in the SERPINA1 gene, which can result in both lung- and liver-related symptoms, including shortness of breath, wheezing, chronic cough and frequent chest colds, as well as jaundice, ascites, and cirrhosis. There are currently no disease-modifying or curative treatments approved for the approximately 200,000 people in the United States and European Union with AATD, of which 20,000-30,000 people are currently diagnosed. Many patients with AATD ultimately progress to liver failure or severe lung disease, eventually resulting in premature death. Prime Medicine will also continue its in vivo Cystic Fibrosis program with support from the Cystic Fibrosis Foundation, and its efforts to develop Prime Edited CAR-T products for hematology, immunology and oncology in partnership with Bristol Myers Squibb. As announced in conjunction with initial data for PM359 this morning, Prime Medicine is exploring options for the continued clinical development of PM359 external to the company and ceasing further efforts in X-linked CGD. Prime Medicine believes PM359 has the potential to transform the care of p47 CGD and is committed to working with urgency to identify an appropriate partner to help ensure this important therapy is delivered to patients.Seeking Alpha • Apr 25Prime Medicine: Initiating Coverage At Hold With 2025 Binary Catalyst For PM359Summary Initiate Hold on Prime Medicine due to pending Phase 1/2 CGD readout in 2025 and Wilson’s Disease IND filing in 2026, focusing on safety and mechanistic editing. Await six-month durability data in 2026 or clear non-dilutive funding before re-rating, given rising R&D spend and cash runway into mid-2026. PM359 readout seen as a small catalyst; significant share movement depends on demonstrating lasting infection reduction and stable blood counts. The competitive landscape includes Rocket Pharma’s lentiviral RP-L102 and CRISPR Therapeutics’ Cas9-edited HSC trials; PM359’s modular assay development offers lower off-target risk. Read the full article on Seeking Alphaお知らせ • Apr 23Prime Medicine, Inc., Annual General Meeting, Jun 04, 2025Prime Medicine, Inc., Annual General Meeting, Jun 04, 2025.お知らせ • Mar 18Prime Medicine, Inc. Unveils Program for the Treatment of Alpha-1 Antitrypsin DeficiencyPrime Medicine, Inc. unveiled a preclinical program for the treatment of alpha-1 antitrypsin deficiency (AATD), the next program within its liver franchise. Prime Medicine expects to file an investigational new drug (IND) and/or clinical trial application (CTA) in mid-2026. Prime Medicine’s Approach to AATD: Prime Medicine’s program leverages the Company’s universal liver lipid nanoparticle (LNP) to edit the E342K (PiZ) mutation in the SERPINA1 gene, the prevalent disease-causing mutation in AATD, restoring the mutated protein sequence back to wild-type M protein, with the potential to treat both lung- and liver-associated disease. In Prime Medicine’s initial in vivo data, LNP delivery of Prime Editors targeting the PiZ (E324K) mutation demonstrated up to 72% precise correction of the SERPINA1 gene in the hepatocytes of fully humanized mice. Importantly, this restored over 95% of serum AAT to the corrected isoform, with healthy AAT (M-AAT) protein in the serum at levels well above 20µM, indicating restoration of M-AAT to normal levels in a humanized mouse model. Prime Medicine’s universal LNP contains a GalNAc-targeting ligand (GalNAc-LNP), a validated component for liver-specific delivery of gene editors. In preclinical studies, delivery of Prime Editors using a GalNAc-LNP has demonstrated increased potency, and both an improved safety profile and biodistribution when benchmarked against other LNPs that have gone into the clinic. Preclinical studies using unoptimized surrogate Prime Editors for genetic diseases in non-human primate (NHP) models showed greater than 50% editing, with an excellent safety profile, and no detectable off-target edits or unintended edits at the target site. Based on these data, Prime Medicine believes Prime Editing has the ability to correct disease-causing mutations with high efficiency, without introducing off-target or bystander edits. Prime Medicine is advancing its AATD program through the final stages of lead optimization and expects to file an IND and/or CTA filing in mid-2026. AATD is a progressive, genetic disorder caused by mutations in the SERPINA1 gene; these mutations lead to decreased levels of circulating AAT protein in the blood, as well as the build-up of toxic mutant AAT protein in the liver. Because the primary function of AAT is to protect lungs from inflammation caused by infection and inhaled irritants, low levels of circulating AAT can result in lung-related symptoms, including shortness of breath, wheezing, chronic cough and frequent chest colds. Additionally, the build-up of abnormal AAT in the liver can cause jaundice, ascites, and cirrhosis. There are currently no disease-modifying or curative treatments approved for the approximately 200,000 people in the United States and European Union with AATD, and many patients ultimately progress to liver failure or severe lung disease, eventually resulting in premature death.Seeking Alpha • Feb 05Prime Medicine: Gene Editing Company, Risky InvestmentSummary Prime Medicine, Inc. develops prime editing technologies but lacks proof of concept data despite being in the market for 6 years and IPO for 3 years. The gene editing sector is highly risky, with poor performers like Editas Medicine and Beam Therapeutics highlighting the volatility and challenges in clinical success. PRME's financials show a market cap of $338mn and a cash runway into 2026, but significant risks remain if clinical data is not favorable. Despite some positive developments, including a partnership with Bristol Myers Squibb, retail investors should exercise caution due to the high risk and low cash runway. Read the full article on Seeking Alpha分析記事 • Dec 19Is Prime Medicine (NASDAQ:PRME) In A Good Position To Deliver On Growth Plans?Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...Seeking Alpha • Nov 26Prime Medicine's Bristol Myers Partnership Boosts Outlook For Gene Editing TherapiesSummary Prime Medicine’s proprietary Prime Editing platform offers one-time therapeutic solutions, targeting over 90% of genetic conditions across multiple tissues and development stages. PRME’s pipeline highlights PM359 for chronic granulomatous disease and preclinical programs for Wilson’s Disease, with clinical data expected in 2025. PRME's strategic collaboration with Bristol Myers provided $55 million in cash upfront, a $55 million equity stake, $3.5B in potential milestone payments, and diversification into ex vivo T-cell therapies. Still, investment risks include dependency on milestone achievements and potential future equity raises, but current valuation and prospects make PRME a compelling investment. Despite remaining speculative, PRME’s improved financial position, strategic partnerships, and pipeline progress justify an upgraded "Buy" rating. Read the full article on Seeking AlphaSeeking Alpha • Sep 04Prime Medicine's Promising Pipeline: PM359 And Cash Burn ConcernsSummary Prime Medicine's Prime Editing offers precise, adaptable, and safer gene-editing treatments, with PM359 for Chronic Granulomatous Disease recently cleared for clinical trials. PRME’s lead drug candidate, PM359, was cleared by the FDA in April 2024 and is in Phase 1/2 clinical trials for Chronic Granulomatous Disease. PRME's short-term liquidity is $162.9 million, but its high cash burn suggests it'll need additional financing in the near term. I rate PRME as a “Hold” due to its promising technology but significant cash burn and dilution risks. Read the full article on Seeking Alpha分析記事 • Sep 04Here's Why We're A Bit Worried About Prime Medicine's (NASDAQ:PRME) Cash Burn SituationEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Seeking Alpha • Jun 20Prime Medicine Stock: Only For The Most Patient Of InvestorsSummary We take our first look at gene editing concern Prime Medicine, Inc., whose stock was recently upgraded by Citigroup. The company has an extensive set of potential candidates in pre-clinical research and just advanced its first gene therapy asset in clinical stage development. An analysis around Prime Medicine follows in the paragraphs below. Read the full article on Seeking Alpha分析記事 • May 14Is Prime Medicine (NASDAQ:PRME) In A Good Position To Invest In Growth?Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...お知らせ • May 01Prime Medicine, Inc., Annual General Meeting, Jun 12, 2024Prime Medicine, Inc., Annual General Meeting, Jun 12, 2024, at 14:00 US Eastern Standard Time. Agenda: To elect Wendy Chung, M.D., Ph.D., Kaye Foster, Keith Gottesdiener, M.D., and Jeffrey Marrazzo as Class II Directors, each to serve until the 2027 annual meeting of stockholders, and until his or her respective successor shall have been duly elected and qualified, or until his or her earlier death, resignation or removal; to approve an amendment to third amended and restated certificate of incorporation to limit the liability of certain of officers as permitted by Delaware law; to ratify the appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm for the fiscal year ending December 31, 2024 and to transact such other business as may properly come before the Annual Meeting or any continuations, adjournments, and postponements thereof.お知らせ • Apr 30Prime Medicine Announces FDA Clearance of Investigational New Drug (IND) Application for PM359 for the Treatment of Chronic Granulomatous Disease (CGD)Prime Medicine, Inc. announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application for PM359, submitted on March 29, for the treatment of chronic granulomatous disease (CGD), enabling the Company to initiate its global Phase 1/2 clinical trial in the United States. The Phase 1/2 clinical trial is a multinational, first-in-human trial designed to assess the safety, biological activity and preliminary efficacy of PM359 in adult and pediatric study participants. Initial study participants will be adults with stable disease. If safety and biological activity are demonstrated in this cohort, the study is designed to enroll participants with active infection or severe inflammation as well as adolescent and pediatric participants. Participants will be followed for safety, including engraftment and reconstitution of the hematopoietic system, early biological markers of restored immune function, and long-term resolution and prevention of infectious and inflammatory complications of CGD. Prime Medicine expects to report initial clinical data from the study in 2025.お知らせ • Feb 16+ 2 more updatesPrime Medicine, Inc. has completed a Follow-on Equity Offering in the amount of $140.000006 million.Prime Medicine, Inc. has completed a Follow-on Equity Offering in the amount of $140.000006 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 19,200,001 Price\Range: $6.25 Discount Per Security: $0.375 Security Name: Pre-Funded Warrants Security Type: Equity Warrant Securities Offered: 3,200,005 Price\Range: $6.24999 Discount Per Security: $0.375お知らせ • Feb 15+ 1 more updatePrime Medicine, Inc. has completed a Follow-on Equity Offering in the amount of $140.000005 million.Prime Medicine, Inc. has completed a Follow-on Equity Offering in the amount of $140.000005 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 19,200,001 Price\Range: $6.25 Security Name: Pre-Funded Warrants Security Type: Equity Warrant Securities Offered: 3,200,005 Price\Range: $6.24999Seeking Alpha • Jan 28Prime Medicine's Investment Potential: A Deep Dive Into Innovation And Gene EditingSummary Prime Medicine is a gene editing company at the forefront of genetic therapies, with a promising pipeline and preclinical successes. The company has made substantial investments in R&D, demonstrating its commitment to innovation and belief in its technology. Despite financial losses, Prime Medicine maintains a strong cash position, providing stability and flexibility for future growth. Read the full article on Seeking Alphaお知らせ • Jan 07Prime Medicine Announces Chief Financial Officer Changes, Effective January 17, 2024Prime Medicine, Inc. announced the appointment of Allan Reine, M.D., as the Company’s Chief Financial Officer, effective January 17, 2024. Dr. Reine, age 49, a seasoned financial executive with over twenty years’ experience in the biotechnology industry, Dr. Reine will be responsible for the company’s financing strategy and investor relations, and will oversee all financial operations as Prime Medicine begins its transition into a clinical company. Prior to joining Prime Medicine, Dr. Reine was Chief Financial Officer at Foghorn Therapeutics and, before that, at Pieris Pharmaceuticals. Dr. Reine also serves as Chairman of the Board of ONK Therapeutics. Previously, Dr. Reine managed various healthcare portfolios primarily focused on biotechnology and pharmaceutical companies at Lombard Odier Asset Management, Citi Principal Strategies, SAC Capital, Trivium Capital and Alexandra Investment Management. He started his career at CIBC World Markets where he worked in both biotechnology investment banking and biotechnology equity research. Dr. Reine received his M.D. from the University of Toronto, and his Bachelor of Science in statistical sciences from the University of Western Ontario. Effective January 17, 2024, Carman Alenson will transition from Interim Chief Financial Officer and Chief Accounting Officer to Senior Vice President, Finance and Chief Accounting Officer. She will step down from the role of principal financial officer and will continue in her role of principal accounting officer.お知らせ • Jan 06Prime Medicine, Inc. Announces Executive Changes, Effective January 17, 2024On January 4, 2024, the Board of Directors of Prime Medicine, Inc. appointed Allan Reine as the principal financial officer of the company effective as of January 17, 2024. Dr. Reine, age 49, has over 20 years of experience in the biotechnology sector. Prior to joining the Company, he was Chief Financial Officer of Foghorn Therapeutics, Inc., a biotechnology company, from September 2019 to January 2024 and Chief Financial Officer of Pieris Pharmaceuticals, Inc. from August 2017 to September 2019. Previously, Dr. Reine managed various healthcare portfolios primarily focused on biotechnology and pharmaceutical companies at Lombard Odier Asset Management, Citi Principal Strategies, SAC Capital, Trivium Capital and Alexandra Investment Management. He started his career at CIBC World Markets where he worked in both biotechnology investment banking and biotechnology equity research. Dr. Reine is currently chairman of the board of directors of ONK Therapeutics, Inc. where he has served on the board of directors since March 2022. Dr. Reine received his M.D. from the University of Toronto and his B.S. in Statistical Sciences from the University of Western Ontario. Effective January 17, 2024, Carman Alenson will transition from Interim Chief Financial Officer and Chief Accounting Officer to Senior Vice President, Finance and Chief Accounting Officer. She will step down from the role of principal financial officer and will continue in her role of principal accounting officer.Price Target Changed • Dec 08Price target decreased by 10% to US$19.71Down from US$22.00, the current price target is an average from 7 analysts. New target price is 132% above last closing price of US$8.50. Stock is down 50% over the past year. The company is forecast to post a net loss per share of US$1.94 next year compared to a net loss per share of US$4.19 last year.お知らせ • Oct 28Prime Medicine, Inc. Presents First-Ever Prime Editing Data in Non-Human Primates Demonstrating Highly Efficient Ability of Prime Editors to Precisely Correct Disease-Causing Mutation of Gsd1bPrime Medicine, Inc. reported new preclinical data demonstrating the ability of liver-targeted Prime Editors to efficiently and precisely correct one of the most prevalent disease-causing mutations of glycogen storage disease 1b (GSD1b) in non-human primates (NHP) and mouse models. The data were presented at the European Society of Gene and Cell Therapy (ESGCT) 2023 Congress in Brussels, Belgium. GSD1b is a rare, serious progressive disease that causes impaired glycogen metabolism and affects approximately 1,500 patients. It results from mutations in the glucose-6-phosphate transporter (G6PT), which is encoded by the gene SLC37A4. Deficiencies in this transporter result in hypoglycemia, or low blood glucose levels, which can be fatal if patients do not adhere to a strict dietary regimen, including consuming slow-release glucose and overnight feeding. P.L348fs and p.G339C mutations are known to be the most prevalent disease-causing mutations and are found in approximately 46-52% of the GSD1b patient population. According to scientific literature and Prime Medicine research, correcting SLC37A4 gene mutations in fewer than 10% of liver cells may be sufficient to reverse many manifestations of this disease. To address the underlying genetic cause of GSD1b, Prime Medicine is advancing Prime Editors that are delivered to the liver by single intravenous infusion and designed to enable a precise correction of the disease-causing mutations, restoring G6PT protein expression and glucose homeostasis. The Prime Editors are composed of a Prime Editor guide RNA (pegRNA) targeting the respective mutations, a nick-guide RNA (ngRNA) and a messenger RNA (mRNA) packaged in Prime’s universal lipid nanoparticle (LNP) formulation that includes a ligand targeting the LNP to hepatocytes. Through high-throughput screening and subsequent optimization, Prime researchers identified pegRNAs that precisely corrected the p.L348fs and p.G339C mutations in liver cells, which were then evaluated in vitro, demonstrating average editing of 77% and 37%, respectively. In today’s presentation at ESGCT, Prime Medicine highlighted data from in vivo rodent and NHP studies with its Prime Editor targeting the p.L348fs mutation. Key findings from the studies showed: Up to 50% whole liver precise editing of p.L348 in NHPs at day 14 without significant on-target unintended edits. Up to 83% of the key target cells, liver hepatocytes, were estimated to have both alleles precisely edited by this single LNP administration. Up to 56% whole liver precise correction of the p.L348fs mutation in a GSD1b humanized mouse model with on-target unintended editing of less than 0.2% across dose levels evaluated. Prime Editing of up to 44% led to restored levels of G6PT protein expression of up to 46%, with the extent of correction directly correlating with the extent of G6PT protein restoration in the humanized mouse model. Redosing of the universal LNP in non-naïve animals was tolerated similarly to naïve animals with no infusion reactions, no body weight changes, and transient, modest liver function changes that resolved by day 7; minimal transient cytokine abnormalities were observed. No detectable off-target edits were observed in patient-derived induced pluripotent stem cells (iPSCs) following a comprehensive off-target screening analysis, consistent with what has been observed to date across Prime Medicine’s extensive off-target analyses for each of its programs. These findings provide important proof-of-concept for Prime Medicine’s LNP liver-targeted delivery approach, and support the further advancement of the Company’s Prime Editors targeting the p.L348fs and p.G339C mutations in GSD1b, as well as its additional liver-targeted programs.お知らせ • Oct 25Prime Medicine, Inc. Presents First in Vivo Proof-Of-Concept Prime Editing Data Demonstrating Ability of Prime Editors to Treat Ophthalmological DiseasesPrime Medicine, Inc. reported new preclinical data demonstrating the ability of Prime Editors to efficiently and precisely correct the predominant mutations that cause rhodopsin associated autosomal dominant retinitis pigmentosa (RHO adRP). The data were presented at the International Symposium on Retinal Degeneration 2023 Congress (RD2023) in Costa del Sol, Spain. RHO adRP is a rare inherited retinal disease that causes progressive vision loss in early adolescence, leading to eventual blindness in adulthood due to photoreceptor degeneration. It results from mutations in the gene RHO, which encourages rhodopsin, the light-sensitive G protein-coupled receptor involved in phototransduction in rods, a type of photoreceptor, and leads to the progressive loss of rods and, subsequently, cones in the retina. Specifically, today's data highlight the ability of two Prime Editors to correct the predominant mutations causing RHO adRP -- one to correct p.P23H, the most common disease-causing mutation in RHO in the U.S., and one to correct 18 different mutations at a mutational hotspot in RHO, including p.V345L and p.P347L, which are the most prevalent mutations in Europe.New Risk • Oct 18New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 9.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 8.2% per year for the foreseeable future. Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$213m net loss in 3 years). Share price has been volatile over the past 3 months (9.5% average weekly change).分析記事 • Aug 25Is Prime Medicine (NASDAQ:PRME) In A Good Position To Deliver On Growth Plans?Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...お知らせ • May 12Prime Medicine, Inc. Appoints Jeff Marrazzo to Its Board of DirectorsPrime Medicine, Inc. announce announced appointment of Jeff Marrazzo, co-founder and former Chief Executive Officer of Spark Therapeutics, Inc., to its Board of Directors. Jeff founded and built Spark Therapeutics from an idea incubated within the Children’s Hospital of Philadelphia (CHOP) into the world’s first fully integrated, commercial gene therapy company with over 850 employees at the time of his departure. Under Jeff’s leadership, Spark developed and launched LUXTURNA® for a rare blinding disorder, the first U.S. Food and Drug Administration-approved gene therapy for a genetic disease in the U.S., spearheading the creation of novel reimbursement models to ensure patient access to genetic medicines. While at Spark, Jeff shepherded multiple gene therapies into the clinic for patients with conditions ranging from inherited retinal diseases to rare bleeding and neuromuscular disorders, raising $1 billion in capital and establishing major partnerships with Pfizer and Novartis. Jeff’s orchestration of Spark’s $4.8 billion sale to Roche in 2019 marked a 100-fold increase in the company’s market value over six years.分析記事 • May 12We're Not Very Worried About Prime Medicine's (NASDAQ:PRME) Cash Burn RateEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...分析記事 • Jan 24Will Prime Medicine (NASDAQ:PRME) Spend Its Cash Wisely?Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Board Change • Nov 16High number of new and inexperienced directorsThere are 11 new directors who have joined the board in the last 3 years. The company's board is composed of: 11 new directors. 1 experienced director. No highly experienced directors. Independent Director David Schenkein is the most experienced director on the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.Board Change • Oct 22High number of new and inexperienced directorsThere are 11 new directors who have joined the board in the last 3 years. The company's board is composed of: 11 new directors. 1 experienced director. No highly experienced directors. Independent Director David Schenkein is the most experienced director on the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.決済の安定と成長配当データの取得安定した配当: PRMEの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。増加する配当: PRMEの配当金が増加しているかどうかを判断するにはデータが不十分です。配当利回り対市場Prime Medicine 配当利回り対市場PRME 配当利回りは市場と比べてどうか？セグメント配当利回り会社 (PRME)n/a市場下位25% (US)1.4%市場トップ25% (US)4.1%業界平均 (Biotechs)2.4%アナリスト予想 (PRME) (最長3年)0%注目すべき配当: PRMEは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。高配当: PRMEは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。株主への利益配当収益カバレッジ: PRMEの 配当性向 を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。株主配当金キャッシュフローカバレッジ: PRMEが配当金を報告していないため、配当金の持続可能性を計算できません。高配当企業の発掘7D1Y7D1Y7D1YUS 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/01 03:07終値2026/06/30 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Prime Medicine, Inc. 11 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。18 アナリスト機関Yevgeniya LivshitsChardan Capital Markets, LLCSamantha Lynn SemenkowCitigroup IncSilvan TuerkcanCitizens JMP Securities, LLC15 その他のアナリストを表示
お知らせ • Jun 22Prime Medicine Receives U.S. Fda Regenerative Medicine Advanced Therapy Designation for Pm359 for the Treatment of Chronic Granulomatous DiseasePrime Medicine, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to PM359, an investigational autologous Prime Edited hematopoietic stem cell therapy for the treatment of p47phox-deficient chronic granulomatous disease (CGD). RMAT designation was granted based on Phase 1/2 clinical data, including data previously published in The New England Journal of Medicine, and will provide the benefits of intensive FDA guidance and expedited review through the program’s development. The combination of RMAT, Fast Track, Orphan Drug, and Rare Pediatric Disease Designations underscores the seriousness of CGD and the need for transformative therapies that deliver durable benefit, while positioning us to engage with the FDA on the most efficient path to a Biologics License Application. RMAT designation was established under the 21st Century Cures Act to expedite the development and review of regenerative medicine therapies intended to treat serious or life-threatening diseases when preliminary clinical evidence indicates the therapy has the potential to address unmet medical need. RMAT designation provides all the benefits of Fast Track and Breakthrough Therapy Designations, including intensive FDA interaction, discussions on surrogate or intermediate endpoints that may support accelerated approval, and eligibility for rolling and priority review of a future Biologics License Application. The initial clinical trial results were reported in the December 2025 publication in The New England Journal of Medicine. The data demonstrate that a single dose of PM359 drove rapid engraftment and a durable, clinically meaningful restoration of immune cell function in both treated patients, with neutrophil activity well above the level associated with clinical benefit and a safety profile consistent with busulfan-based conditioning alone. The findings support the potential of PM359 to deliver a one-time, disease-modifying treatment for patients with p47phox-deficient CGD. PM359 is an investigational autologous hematopoietic stem cell therapy designed to correct the delGT mutation in NCF1, the most prevalent disease-causing mutation in p47phox-deficient CGD. PM359 is being evaluated in an ongoing Phase 1/2, multinational, first-in-human trial. In addition to RMAT designation, PM359 has received Fast Track, Orphan Drug, and Rare Pediatric Disease Designations from the FDA. Chronic granulomatous disease (CGD) is a rare inherited hematologic disorder characterized by susceptibility to severe, difficult-to-treat infections and inflammatory and autoimmune complications. CGD is caused by mutations in any one of the subunits comprising the NADPH oxidase complex, which is required for phagocytic cells, in particular neutrophils, to destroy many invasive microorganisms. CGD causative mutations are estimated to occur in between one in 100,000 and one in 200,000 births in the United States, with the p47phox form accounting for approximately 25% of cases. Current standard of care relies on lifelong antimicrobial prophylaxis and, in select cases, allogeneic hematopoietic stem cell transplantation, which carries significant morbidity and is not accessible to all patients. There are no approved gene editing therapies for CGD.
お知らせ • Jun 19Prime Medicine, Inc. Receives New Zealand Clearance For Clinical Trial Application For PM577a In H1069Q-Mutated Wilson DiseasePrime Medicine, Inc. announced that the New Zealand Medicines and Medical Devices Safety Authority (Medsafe) has cleared the Company’s Clinical Trial Application (CTA) for PM577a, an investigational Prime Editor for Wilson Disease (WD). The clearance represents the first clinical authorization for an in vivo Prime Editing therapy from Prime Medicine and enables the initiation of the Company’s global Phase 1/2 study. The Phase 1/2 clinical trial is an open-label, global, first-in-human study designed to evaluate the safety, tolerability, biological activity, and efficacy of ascending doses of PM577a in adults and adolescents with WD. The study will initially enroll adults who are clinically stable on standard-of-care therapy. Biological activity and efficacy assessments may include copper efflux by 64Cu PET, serum ceruloplasmin, non-ceruloplasmin bound copper, 24-hour urinary copper excretion, and hepatic copper by biopsy. PM577 is a family of LNP-formulated Prime Editing products designed to correct pathogenic ATP7B mutations in hepatocytes via a single intravenous infusion. Prime Medicine’s initial candidate, PM577a, targets the ATP7B H1069Q allele, which accounts for approximately 30–50% of WD-associated variants in the United States and Europe. The Company intends to develop additional products to address the majority of pathogenic variants on a global basis. Currently, a follow-on candidate is in pre-clinical development targeting R778L, the most common mutant allele in East Asian populations.
分析記事 • Jun 18Is Prime Medicine (NASDAQ:PRME) In A Good Position To Invest In Growth?Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Seeking Alpha • Jun 13Prime Medicine's Prime Editing Is Worth The RiskSummary Prime Medicine's PM359 data gives the stock some early human validation for its main value driver: Prime Editing. PM359 was essentially their most advanced application of Prime Editing, even though CGD is a relatively niche market because it's a rare disease. Management decided to deprioritize PM359, and instead, it’s now focused on applying Prime Editing towards larger TAMs like Wilson Disease and AATD. PRME will probably have a lot of interest if they look for new R&D partnerships, which could also help them with financing if they materialize. So, even though I reckon there’s still some dilution and clinical trial risks, PRME’s potentially revolutionary gene editing platform makes it a viable speculative 'Buy.' Read the full article on Seeking Alpha
お知らせ • Apr 25Prime Medicine, Inc., Annual General Meeting, Jun 05, 2026Prime Medicine, Inc., Annual General Meeting, Jun 05, 2026.
お知らせ • Apr 16Prime Medicine, Inc. Appoints Svetlana Makhni as Chief Financial OfficerPrime Medicine, Inc. announced the appointment of Svetlana Makhni as Chief Financial Officer (CFO). Ms. Makhni will oversee Prime Medicine’s financial operations and strategy, including investor relations, financial planning and analysis, and corporate development. Ms. Makhni brings over 20 years of experience across multiple biotechnology and healthcare CFO and investment banking roles. Prior to joining Prime Medicine, she served as CFO of Marengo Therapeutics, a clinical-stage immuno-oncology company, where she led all aspects of the finance organization, including business development, investor relations and corporate development. In this role, Ms. Makhni played a key role in the execution of multiple high-value strategic partnerships, including transactions with Ipsen and Gilead Sciences. Previously, Ms. Makhni served as CFO of Escient Pharmaceuticals and CFO and Head of Operations at Bierman ABA. Earlier in her career, Ms. Makhni spent over a decade in investment banking and financial services at BMO Capital Markets, Goldman Sachs, Westbrook Partners and The Blackstone Group, advising public and private companies on equity and debt financings, mergers and acquisitions, and other strategic transactions. Ms. Makhni holds an M.B.A. from Harvard Business School and a B.S. from the Wharton School of the University of Pennsylvania.
お知らせ • Nov 07Prime Medicine, Inc. has filed a Follow-on Equity Offering in the amount of $200 million.Prime Medicine, Inc. has filed a Follow-on Equity Offering in the amount of $200 million. Security Name: Common Stock Security Type: Common Stock Transaction Features: At the Market Offering
お知らせ • Nov 04Prime Medicine, Inc. Appoints Matthew Hawryluk as Chief Business OfficerPrime Medicine, Inc. announced the appointment of Matthew Hawryluk, Ph.D., M.B.A. as Chief Business Officer (CBO). Dr. Hawryluk will lead Primes corporate and business development initiatives, corporate strategy, and alliance management functions, advancing the companys efforts to expand the reach of Prime Editing through strategic partnerships and collaborations. Dr. Hawryluk joins Prime Medicine with nearly two decades of leadership experience spanning business development, strategy, and corporate operations in the biotechnology industry. Most recently, he served as Chief Business Officer at AIRNA Corporation, where he led corporate and business development, finance, and investor relations, and played a key role in securing an oversubscribed $155 million Series B financing. Dr. Hawryluk served for nearly a decade as Executive Vice President and Chief Business Officer at Gritstone bio, Inc., guiding its growth from early stage to a public company and spearheading its expansion into infectious diseases. He led transactions totaling more than $2.5 billion in potential value, including landmark collaborations with Gilead Sciences, bluebird bio, and multiple government and nonprofit organizations such as BARDA, CEPI, NIAID, and the Bill &Melinda Gates Foundation. Earlier in his career, Dr. Hawryluk held senior roles at Foundation Medicine, where he was instrumental in forging the companys transformative strategic partnership and majority acquisition by Roche/Genentech. His experience also includes business development roles at Thermo Fisher Scientific and work in venture capital and translational science. Dr. Hawryluk holds a Ph.D. in Cell Biology and Protein Biochemistry from the University of Pittsburgh School of Medicine, an M.B.A. from the Carnegie Mellon University Tepper School of Business, and a B.S. in Biochemistry from the University of Notre Dame. Dr. Hawryluk serves on the Boards of Directors of Predictive Oncology Inc. and OuroTech, Inc. (Pear Bio).
お知らせ • Aug 01Prime Medicine, Inc. has completed a Follow-on Equity Offering in the amount of $125.4 million.Prime Medicine, Inc. has completed a Follow-on Equity Offering in the amount of $125.4 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 38,000,000 Price\Range: $3.3 Discount Per Security: $0.198
お知らせ • Jul 31Prime Medicine, Inc. has filed a Follow-on Equity Offering.Prime Medicine, Inc. has filed a Follow-on Equity Offering. Security Name: Common Stock Security Type: Common Stock
お知らせ • Jun 30+ 4 more updatesPrime Medicine, Inc.(NasdaqGM:PRME) dropped from Russell 3000E Growth IndexPrime Medicine, Inc.(NasdaqGM:PRME) dropped from Russell 3000E Growth Index
お知らせ • May 21Prime Medicine, Inc. Announces Breakthrough Clinical Data Showing Rapid Restoration of DHR Positivity After Single Infusion of PM359Prime Medicine, Inc. announced positive initial data from the first patient dosed in its ongoing Phase 1/2 clinical study of PM359 in Chronic Granulomatous Disease (CGD). Preliminary results from the first patient demonstrated that PM359 was well-tolerated, showed rapid engraftment and restored NADPH oxidase activity to well above the threshold for clinical benefit, as measured by the dihydrorhodamine (DHR) assay. Going forward, Prime Medicine will focus its resources on advancing its in vivo liver franchise, where the Company is advancing programs to cure two of the largest genetic liver diseases, Wilson's Disease and Alpha-1 Antitrypsin Deficiency (AATD). Prime Medicine will also continue its in vivo Cystic Fibrosis program with support from the Cystic Fibrosis Foundation, and its efforts to develop Prime Edited CAR-T products for hematology, immunology and oncology in partnership with Bristol Myers Squibb. In addition, Prime Medicine will continue to pursue additional business development opportunities to accelerate innovation, ensure the broadest application of Prime Editing, and further bolster its financial resources. PM359 comprisesautologous hematopoietic stem cells (HSCs) modified ex vivo using Prime Editors that have been designed to correct a high percentage of cells containing the disease-causing mutation. PM359 has received rare pediatric drug designation and orphan drug designation from the U.S. Food and Drug Administration. Chronic Granulomatous disease (CGD) is a rare inherited hematologic disorder characterized by susceptibility to severe, difficult-to-treat infections, and inflammatory/autoimmune complications.
お知らせ • May 20+ 3 more updatesPrime Medicine, Inc. Provides Pipeline Prioritization UpdatePrime Medicine, Inc. announced a strategic restructuring, including the deprioritization of its Chronic Granulomatous Disease (CGD) programs. Prime Medicine is currently advancing in vivo programs to cure two of the largest genetic liver diseases, Wilson’s Disease and Alpha-1 Antitrypsin Deficiency (AATD), with initial clinical data from both programs expected in 2027. Prime Medicine will also continue its in vivo Cystic Fibrosis program with support from the Cystic Fibrosis Foundation, and its efforts to develop Prime Edited CAR-T products for hematology, immunology and oncology in partnership with Bristol Myers Squibb. In addition, Prime Medicine will continue to pursue additional business development opportunities to accelerate innovation, ensure the broadest application of Prime Editing, and further bolster its financial resources. Prime Medicine will focus its internal efforts on the development of in vivo programs for the treatment of Wilson’s Disease and AATD, two of the largest genetic liver diseases. Prime Medicine expects to file an investigational new drug (IND) and/or clinical trial application (CTA) for its Wilson’s Disease program in the first half of 2026 and for its AATD program in mid-2026; initial clinical data from both programs are expected in 2027. Wilson’s Disease: Wilson’s Disease is a rare and severe disorder caused by excess copper accumulation in the liver and brain that can lead to liver failure and neurocognitive decline and can be fatal without a liver transplant. There are currently no approved disease-modifying therapies for Wilson’s Disease, which affects more than 20,000 people in the United States and European Union. AATD: AATD is a progressive, genetic disorder caused by mutations in the SERPINA1 gene, which can result in both lung- and liver-related symptoms, including shortness of breath, wheezing, chronic cough and frequent chest colds, as well as jaundice, ascites, and cirrhosis. There are currently no disease-modifying or curative treatments approved for the approximately 200,000 people in the United States and European Union with AATD, of which 20,000-30,000 people are currently diagnosed. Many patients with AATD ultimately progress to liver failure or severe lung disease, eventually resulting in premature death. Prime Medicine will also continue its in vivo Cystic Fibrosis program with support from the Cystic Fibrosis Foundation, and its efforts to develop Prime Edited CAR-T products for hematology, immunology and oncology in partnership with Bristol Myers Squibb. As announced in conjunction with initial data for PM359 this morning, Prime Medicine is exploring options for the continued clinical development of PM359 external to the company and ceasing further efforts in X-linked CGD. Prime Medicine believes PM359 has the potential to transform the care of p47 CGD and is committed to working with urgency to identify an appropriate partner to help ensure this important therapy is delivered to patients.
Seeking Alpha • Apr 25Prime Medicine: Initiating Coverage At Hold With 2025 Binary Catalyst For PM359Summary Initiate Hold on Prime Medicine due to pending Phase 1/2 CGD readout in 2025 and Wilson’s Disease IND filing in 2026, focusing on safety and mechanistic editing. Await six-month durability data in 2026 or clear non-dilutive funding before re-rating, given rising R&D spend and cash runway into mid-2026. PM359 readout seen as a small catalyst; significant share movement depends on demonstrating lasting infection reduction and stable blood counts. The competitive landscape includes Rocket Pharma’s lentiviral RP-L102 and CRISPR Therapeutics’ Cas9-edited HSC trials; PM359’s modular assay development offers lower off-target risk. Read the full article on Seeking Alpha
お知らせ • Apr 23Prime Medicine, Inc., Annual General Meeting, Jun 04, 2025Prime Medicine, Inc., Annual General Meeting, Jun 04, 2025.
お知らせ • Mar 18Prime Medicine, Inc. Unveils Program for the Treatment of Alpha-1 Antitrypsin DeficiencyPrime Medicine, Inc. unveiled a preclinical program for the treatment of alpha-1 antitrypsin deficiency (AATD), the next program within its liver franchise. Prime Medicine expects to file an investigational new drug (IND) and/or clinical trial application (CTA) in mid-2026. Prime Medicine’s Approach to AATD: Prime Medicine’s program leverages the Company’s universal liver lipid nanoparticle (LNP) to edit the E342K (PiZ) mutation in the SERPINA1 gene, the prevalent disease-causing mutation in AATD, restoring the mutated protein sequence back to wild-type M protein, with the potential to treat both lung- and liver-associated disease. In Prime Medicine’s initial in vivo data, LNP delivery of Prime Editors targeting the PiZ (E324K) mutation demonstrated up to 72% precise correction of the SERPINA1 gene in the hepatocytes of fully humanized mice. Importantly, this restored over 95% of serum AAT to the corrected isoform, with healthy AAT (M-AAT) protein in the serum at levels well above 20µM, indicating restoration of M-AAT to normal levels in a humanized mouse model. Prime Medicine’s universal LNP contains a GalNAc-targeting ligand (GalNAc-LNP), a validated component for liver-specific delivery of gene editors. In preclinical studies, delivery of Prime Editors using a GalNAc-LNP has demonstrated increased potency, and both an improved safety profile and biodistribution when benchmarked against other LNPs that have gone into the clinic. Preclinical studies using unoptimized surrogate Prime Editors for genetic diseases in non-human primate (NHP) models showed greater than 50% editing, with an excellent safety profile, and no detectable off-target edits or unintended edits at the target site. Based on these data, Prime Medicine believes Prime Editing has the ability to correct disease-causing mutations with high efficiency, without introducing off-target or bystander edits. Prime Medicine is advancing its AATD program through the final stages of lead optimization and expects to file an IND and/or CTA filing in mid-2026. AATD is a progressive, genetic disorder caused by mutations in the SERPINA1 gene; these mutations lead to decreased levels of circulating AAT protein in the blood, as well as the build-up of toxic mutant AAT protein in the liver. Because the primary function of AAT is to protect lungs from inflammation caused by infection and inhaled irritants, low levels of circulating AAT can result in lung-related symptoms, including shortness of breath, wheezing, chronic cough and frequent chest colds. Additionally, the build-up of abnormal AAT in the liver can cause jaundice, ascites, and cirrhosis. There are currently no disease-modifying or curative treatments approved for the approximately 200,000 people in the United States and European Union with AATD, and many patients ultimately progress to liver failure or severe lung disease, eventually resulting in premature death.
Seeking Alpha • Feb 05Prime Medicine: Gene Editing Company, Risky InvestmentSummary Prime Medicine, Inc. develops prime editing technologies but lacks proof of concept data despite being in the market for 6 years and IPO for 3 years. The gene editing sector is highly risky, with poor performers like Editas Medicine and Beam Therapeutics highlighting the volatility and challenges in clinical success. PRME's financials show a market cap of $338mn and a cash runway into 2026, but significant risks remain if clinical data is not favorable. Despite some positive developments, including a partnership with Bristol Myers Squibb, retail investors should exercise caution due to the high risk and low cash runway. Read the full article on Seeking Alpha
分析記事 • Dec 19Is Prime Medicine (NASDAQ:PRME) In A Good Position To Deliver On Growth Plans?Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Seeking Alpha • Nov 26Prime Medicine's Bristol Myers Partnership Boosts Outlook For Gene Editing TherapiesSummary Prime Medicine’s proprietary Prime Editing platform offers one-time therapeutic solutions, targeting over 90% of genetic conditions across multiple tissues and development stages. PRME’s pipeline highlights PM359 for chronic granulomatous disease and preclinical programs for Wilson’s Disease, with clinical data expected in 2025. PRME's strategic collaboration with Bristol Myers provided $55 million in cash upfront, a $55 million equity stake, $3.5B in potential milestone payments, and diversification into ex vivo T-cell therapies. Still, investment risks include dependency on milestone achievements and potential future equity raises, but current valuation and prospects make PRME a compelling investment. Despite remaining speculative, PRME’s improved financial position, strategic partnerships, and pipeline progress justify an upgraded "Buy" rating. Read the full article on Seeking Alpha
Seeking Alpha • Sep 04Prime Medicine's Promising Pipeline: PM359 And Cash Burn ConcernsSummary Prime Medicine's Prime Editing offers precise, adaptable, and safer gene-editing treatments, with PM359 for Chronic Granulomatous Disease recently cleared for clinical trials. PRME’s lead drug candidate, PM359, was cleared by the FDA in April 2024 and is in Phase 1/2 clinical trials for Chronic Granulomatous Disease. PRME's short-term liquidity is $162.9 million, but its high cash burn suggests it'll need additional financing in the near term. I rate PRME as a “Hold” due to its promising technology but significant cash burn and dilution risks. Read the full article on Seeking Alpha
分析記事 • Sep 04Here's Why We're A Bit Worried About Prime Medicine's (NASDAQ:PRME) Cash Burn SituationEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Jun 20Prime Medicine Stock: Only For The Most Patient Of InvestorsSummary We take our first look at gene editing concern Prime Medicine, Inc., whose stock was recently upgraded by Citigroup. The company has an extensive set of potential candidates in pre-clinical research and just advanced its first gene therapy asset in clinical stage development. An analysis around Prime Medicine follows in the paragraphs below. Read the full article on Seeking Alpha
分析記事 • May 14Is Prime Medicine (NASDAQ:PRME) In A Good Position To Invest In Growth?Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
お知らせ • May 01Prime Medicine, Inc., Annual General Meeting, Jun 12, 2024Prime Medicine, Inc., Annual General Meeting, Jun 12, 2024, at 14:00 US Eastern Standard Time. Agenda: To elect Wendy Chung, M.D., Ph.D., Kaye Foster, Keith Gottesdiener, M.D., and Jeffrey Marrazzo as Class II Directors, each to serve until the 2027 annual meeting of stockholders, and until his or her respective successor shall have been duly elected and qualified, or until his or her earlier death, resignation or removal; to approve an amendment to third amended and restated certificate of incorporation to limit the liability of certain of officers as permitted by Delaware law; to ratify the appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm for the fiscal year ending December 31, 2024 and to transact such other business as may properly come before the Annual Meeting or any continuations, adjournments, and postponements thereof.
お知らせ • Apr 30Prime Medicine Announces FDA Clearance of Investigational New Drug (IND) Application for PM359 for the Treatment of Chronic Granulomatous Disease (CGD)Prime Medicine, Inc. announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application for PM359, submitted on March 29, for the treatment of chronic granulomatous disease (CGD), enabling the Company to initiate its global Phase 1/2 clinical trial in the United States. The Phase 1/2 clinical trial is a multinational, first-in-human trial designed to assess the safety, biological activity and preliminary efficacy of PM359 in adult and pediatric study participants. Initial study participants will be adults with stable disease. If safety and biological activity are demonstrated in this cohort, the study is designed to enroll participants with active infection or severe inflammation as well as adolescent and pediatric participants. Participants will be followed for safety, including engraftment and reconstitution of the hematopoietic system, early biological markers of restored immune function, and long-term resolution and prevention of infectious and inflammatory complications of CGD. Prime Medicine expects to report initial clinical data from the study in 2025.
お知らせ • Feb 16+ 2 more updatesPrime Medicine, Inc. has completed a Follow-on Equity Offering in the amount of $140.000006 million.Prime Medicine, Inc. has completed a Follow-on Equity Offering in the amount of $140.000006 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 19,200,001 Price\Range: $6.25 Discount Per Security: $0.375 Security Name: Pre-Funded Warrants Security Type: Equity Warrant Securities Offered: 3,200,005 Price\Range: $6.24999 Discount Per Security: $0.375
お知らせ • Feb 15+ 1 more updatePrime Medicine, Inc. has completed a Follow-on Equity Offering in the amount of $140.000005 million.Prime Medicine, Inc. has completed a Follow-on Equity Offering in the amount of $140.000005 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 19,200,001 Price\Range: $6.25 Security Name: Pre-Funded Warrants Security Type: Equity Warrant Securities Offered: 3,200,005 Price\Range: $6.24999
Seeking Alpha • Jan 28Prime Medicine's Investment Potential: A Deep Dive Into Innovation And Gene EditingSummary Prime Medicine is a gene editing company at the forefront of genetic therapies, with a promising pipeline and preclinical successes. The company has made substantial investments in R&D, demonstrating its commitment to innovation and belief in its technology. Despite financial losses, Prime Medicine maintains a strong cash position, providing stability and flexibility for future growth. Read the full article on Seeking Alpha
お知らせ • Jan 07Prime Medicine Announces Chief Financial Officer Changes, Effective January 17, 2024Prime Medicine, Inc. announced the appointment of Allan Reine, M.D., as the Company’s Chief Financial Officer, effective January 17, 2024. Dr. Reine, age 49, a seasoned financial executive with over twenty years’ experience in the biotechnology industry, Dr. Reine will be responsible for the company’s financing strategy and investor relations, and will oversee all financial operations as Prime Medicine begins its transition into a clinical company. Prior to joining Prime Medicine, Dr. Reine was Chief Financial Officer at Foghorn Therapeutics and, before that, at Pieris Pharmaceuticals. Dr. Reine also serves as Chairman of the Board of ONK Therapeutics. Previously, Dr. Reine managed various healthcare portfolios primarily focused on biotechnology and pharmaceutical companies at Lombard Odier Asset Management, Citi Principal Strategies, SAC Capital, Trivium Capital and Alexandra Investment Management. He started his career at CIBC World Markets where he worked in both biotechnology investment banking and biotechnology equity research. Dr. Reine received his M.D. from the University of Toronto, and his Bachelor of Science in statistical sciences from the University of Western Ontario. Effective January 17, 2024, Carman Alenson will transition from Interim Chief Financial Officer and Chief Accounting Officer to Senior Vice President, Finance and Chief Accounting Officer. She will step down from the role of principal financial officer and will continue in her role of principal accounting officer.
お知らせ • Jan 06Prime Medicine, Inc. Announces Executive Changes, Effective January 17, 2024On January 4, 2024, the Board of Directors of Prime Medicine, Inc. appointed Allan Reine as the principal financial officer of the company effective as of January 17, 2024. Dr. Reine, age 49, has over 20 years of experience in the biotechnology sector. Prior to joining the Company, he was Chief Financial Officer of Foghorn Therapeutics, Inc., a biotechnology company, from September 2019 to January 2024 and Chief Financial Officer of Pieris Pharmaceuticals, Inc. from August 2017 to September 2019. Previously, Dr. Reine managed various healthcare portfolios primarily focused on biotechnology and pharmaceutical companies at Lombard Odier Asset Management, Citi Principal Strategies, SAC Capital, Trivium Capital and Alexandra Investment Management. He started his career at CIBC World Markets where he worked in both biotechnology investment banking and biotechnology equity research. Dr. Reine is currently chairman of the board of directors of ONK Therapeutics, Inc. where he has served on the board of directors since March 2022. Dr. Reine received his M.D. from the University of Toronto and his B.S. in Statistical Sciences from the University of Western Ontario. Effective January 17, 2024, Carman Alenson will transition from Interim Chief Financial Officer and Chief Accounting Officer to Senior Vice President, Finance and Chief Accounting Officer. She will step down from the role of principal financial officer and will continue in her role of principal accounting officer.
Price Target Changed • Dec 08Price target decreased by 10% to US$19.71Down from US$22.00, the current price target is an average from 7 analysts. New target price is 132% above last closing price of US$8.50. Stock is down 50% over the past year. The company is forecast to post a net loss per share of US$1.94 next year compared to a net loss per share of US$4.19 last year.
お知らせ • Oct 28Prime Medicine, Inc. Presents First-Ever Prime Editing Data in Non-Human Primates Demonstrating Highly Efficient Ability of Prime Editors to Precisely Correct Disease-Causing Mutation of Gsd1bPrime Medicine, Inc. reported new preclinical data demonstrating the ability of liver-targeted Prime Editors to efficiently and precisely correct one of the most prevalent disease-causing mutations of glycogen storage disease 1b (GSD1b) in non-human primates (NHP) and mouse models. The data were presented at the European Society of Gene and Cell Therapy (ESGCT) 2023 Congress in Brussels, Belgium. GSD1b is a rare, serious progressive disease that causes impaired glycogen metabolism and affects approximately 1,500 patients. It results from mutations in the glucose-6-phosphate transporter (G6PT), which is encoded by the gene SLC37A4. Deficiencies in this transporter result in hypoglycemia, or low blood glucose levels, which can be fatal if patients do not adhere to a strict dietary regimen, including consuming slow-release glucose and overnight feeding. P.L348fs and p.G339C mutations are known to be the most prevalent disease-causing mutations and are found in approximately 46-52% of the GSD1b patient population. According to scientific literature and Prime Medicine research, correcting SLC37A4 gene mutations in fewer than 10% of liver cells may be sufficient to reverse many manifestations of this disease. To address the underlying genetic cause of GSD1b, Prime Medicine is advancing Prime Editors that are delivered to the liver by single intravenous infusion and designed to enable a precise correction of the disease-causing mutations, restoring G6PT protein expression and glucose homeostasis. The Prime Editors are composed of a Prime Editor guide RNA (pegRNA) targeting the respective mutations, a nick-guide RNA (ngRNA) and a messenger RNA (mRNA) packaged in Prime’s universal lipid nanoparticle (LNP) formulation that includes a ligand targeting the LNP to hepatocytes. Through high-throughput screening and subsequent optimization, Prime researchers identified pegRNAs that precisely corrected the p.L348fs and p.G339C mutations in liver cells, which were then evaluated in vitro, demonstrating average editing of 77% and 37%, respectively. In today’s presentation at ESGCT, Prime Medicine highlighted data from in vivo rodent and NHP studies with its Prime Editor targeting the p.L348fs mutation. Key findings from the studies showed: Up to 50% whole liver precise editing of p.L348 in NHPs at day 14 without significant on-target unintended edits. Up to 83% of the key target cells, liver hepatocytes, were estimated to have both alleles precisely edited by this single LNP administration. Up to 56% whole liver precise correction of the p.L348fs mutation in a GSD1b humanized mouse model with on-target unintended editing of less than 0.2% across dose levels evaluated. Prime Editing of up to 44% led to restored levels of G6PT protein expression of up to 46%, with the extent of correction directly correlating with the extent of G6PT protein restoration in the humanized mouse model. Redosing of the universal LNP in non-naïve animals was tolerated similarly to naïve animals with no infusion reactions, no body weight changes, and transient, modest liver function changes that resolved by day 7; minimal transient cytokine abnormalities were observed. No detectable off-target edits were observed in patient-derived induced pluripotent stem cells (iPSCs) following a comprehensive off-target screening analysis, consistent with what has been observed to date across Prime Medicine’s extensive off-target analyses for each of its programs. These findings provide important proof-of-concept for Prime Medicine’s LNP liver-targeted delivery approach, and support the further advancement of the Company’s Prime Editors targeting the p.L348fs and p.G339C mutations in GSD1b, as well as its additional liver-targeted programs.
お知らせ • Oct 25Prime Medicine, Inc. Presents First in Vivo Proof-Of-Concept Prime Editing Data Demonstrating Ability of Prime Editors to Treat Ophthalmological DiseasesPrime Medicine, Inc. reported new preclinical data demonstrating the ability of Prime Editors to efficiently and precisely correct the predominant mutations that cause rhodopsin associated autosomal dominant retinitis pigmentosa (RHO adRP). The data were presented at the International Symposium on Retinal Degeneration 2023 Congress (RD2023) in Costa del Sol, Spain. RHO adRP is a rare inherited retinal disease that causes progressive vision loss in early adolescence, leading to eventual blindness in adulthood due to photoreceptor degeneration. It results from mutations in the gene RHO, which encourages rhodopsin, the light-sensitive G protein-coupled receptor involved in phototransduction in rods, a type of photoreceptor, and leads to the progressive loss of rods and, subsequently, cones in the retina. Specifically, today's data highlight the ability of two Prime Editors to correct the predominant mutations causing RHO adRP -- one to correct p.P23H, the most common disease-causing mutation in RHO in the U.S., and one to correct 18 different mutations at a mutational hotspot in RHO, including p.V345L and p.P347L, which are the most prevalent mutations in Europe.
New Risk • Oct 18New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 9.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 8.2% per year for the foreseeable future. Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$213m net loss in 3 years). Share price has been volatile over the past 3 months (9.5% average weekly change).
分析記事 • Aug 25Is Prime Medicine (NASDAQ:PRME) In A Good Position To Deliver On Growth Plans?Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
お知らせ • May 12Prime Medicine, Inc. Appoints Jeff Marrazzo to Its Board of DirectorsPrime Medicine, Inc. announce announced appointment of Jeff Marrazzo, co-founder and former Chief Executive Officer of Spark Therapeutics, Inc., to its Board of Directors. Jeff founded and built Spark Therapeutics from an idea incubated within the Children’s Hospital of Philadelphia (CHOP) into the world’s first fully integrated, commercial gene therapy company with over 850 employees at the time of his departure. Under Jeff’s leadership, Spark developed and launched LUXTURNA® for a rare blinding disorder, the first U.S. Food and Drug Administration-approved gene therapy for a genetic disease in the U.S., spearheading the creation of novel reimbursement models to ensure patient access to genetic medicines. While at Spark, Jeff shepherded multiple gene therapies into the clinic for patients with conditions ranging from inherited retinal diseases to rare bleeding and neuromuscular disorders, raising $1 billion in capital and establishing major partnerships with Pfizer and Novartis. Jeff’s orchestration of Spark’s $4.8 billion sale to Roche in 2019 marked a 100-fold increase in the company’s market value over six years.
分析記事 • May 12We're Not Very Worried About Prime Medicine's (NASDAQ:PRME) Cash Burn RateEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
分析記事 • Jan 24Will Prime Medicine (NASDAQ:PRME) Spend Its Cash Wisely?Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Board Change • Nov 16High number of new and inexperienced directorsThere are 11 new directors who have joined the board in the last 3 years. The company's board is composed of: 11 new directors. 1 experienced director. No highly experienced directors. Independent Director David Schenkein is the most experienced director on the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
Board Change • Oct 22High number of new and inexperienced directorsThere are 11 new directors who have joined the board in the last 3 years. The company's board is composed of: 11 new directors. 1 experienced director. No highly experienced directors. Independent Director David Schenkein is the most experienced director on the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.